Dual Cancer NGS Panel
This 8-gene panel finds actionable mutations for targeted therapy, helping patients with colorectal and lung cancer to improve outcomes.
CLIA-Certified Lab Service
Research Service
Introducing OptiSeq™ Dual Cancer Panel Kit
The OptiSeq™ Dual Cancer Panel Kit powered with XNA mix Amplification Preparation Kit is a next-generation sequencing (NGS) assay that selectively amplifies and enriches important mutations (APC, BRAF, CTNNB1, EGFR, KRAS, NRAS, PIK3CA, and TP53) at hotspots from lung cancer and colorectal cancer samples using DiaCarta’s proprietary XNA technology. Such an enrichment technology, therefore, improves the downstream sequencing sensitivity by NGS. Without such an enrichment, mutations with low variant allele frequency in the clinical samples may not be detected by NGS (with sensitivity often >1%).
Simple blood test: only 2 tubes of blood needed
Covers 116 mutation hotspots in 8 genes associated with colorectal and lung cancer
Highly sensitive powered by XNA technology
Can be used to monitor low-frequency mutations such as MRD when plasma cfDNA is used for sequencing without deep sequencing
Who will benefit from OptiSeq™?
The OptiSeq™ Dual Cancer Panel Kit covers the detection of APC, BRAF, CTNNB1, EGFR, KRAS, NRAS, PIK3CA and TP53 at hotspots from lung cancer and colorectal cancer samples.
CLIA Labs
CLIA labs that value and validate the panel for targeted therapy selection
Clinical Studies/Trials
Clinical studies or clinical trials that use this panel to profile CRC patients before and/or after drug testing.
The DiaCarta Offerings
SERVICE
OptiSeq™ Dual Cancer Panel Kit is available at DiaCarta CLIA as a Lab-Developed-Test (LDT) or a research use test.